Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Agios Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01915498
First received: July 31, 2013
Last updated: June 1, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: September 2017
  Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)